Amino acid and acylcarnitine levels relate with chronic schizophrenia

Poster (download)

285

Irina Mednova¹, Alexandr Chernonosov², Marat Kasakin³, Elena Kornetova⁴, Arkadiy Semke⁵, Nikolay Bokhan⁶, Vladimir Koval⁷, Svetlana Ivanova^8
1Mental Health Research Institute, TNRMC, Tomsk, Russia, irinka145@yandex.ru
²Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia, alexander.chernonosov@niboch.nsc.ru
³Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia, kassakinm@gmail.com
⁴Mental Health Research Institute, TNRMC, Tomsk, Russia, kornetova@sibmail.com
⁵Mental Health Research Institute, TNRMC, Tomsk, Russia, asemke@mail.ru
⁶Mental Health Research Institute, TNRMC, Tomsk, Russia, mental@tnimc.ru
⁷Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia, koval@niboch.nsc.ru
⁸Mental Health Research Institute, TNRMC, Tomsk, Russia, ivanovaniipz@gmail.com

Amino acids and acylcarnitines play important role as substrates and intermediate products in the most pathways related with schizophrenia. We found a significant decrease in the concentration of valine, aspartate, citrulline, glycine, arginine, glutamate and ornithine as well as C14, C14OH, C16OH, C16:1, C16:1OH, РЎ18, C18OH, C18:1, РЎ18:1OH, C18:2OH and C5:1 and increase C4DC in patients with schizophrenia in comparison to the controls.